- Home
- MCR vs PBYI Comparison
MCR vs PBYI Comparison
Compare MCR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCR
- PBYI
- Stock Information
- Founded
- MCR 1989
- PBYI 2010
- Country
- MCR United States
- PBYI United States
- Employees
- MCR N/A
- PBYI N/A
- Industry
- MCR Trusts Except Educational Religious and Charitable
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- MCR Finance
- PBYI Health Care
- Exchange
- MCR Nasdaq
- PBYI Nasdaq
- Market Cap
- MCR 265.5M
- PBYI 237.2M
- IPO Year
- MCR N/A
- PBYI N/A
- Fundamental
- Price
- MCR $6.42
- PBYI $5.25
- Analyst Decision
- MCR
- PBYI Strong Buy
- Analyst Count
- MCR 0
- PBYI 1
- Target Price
- MCR N/A
- PBYI $7.00
- AVG Volume (30 Days)
- MCR 66.7K
- PBYI 512.6K
- Earning Date
- MCR 01-01-0001
- PBYI 11-06-2025
- Dividend Yield
- MCR 8.52%
- PBYI N/A
- EPS Growth
- MCR N/A
- PBYI 434.29
- EPS
- MCR 0.38
- PBYI 0.97
- Revenue
- MCR N/A
- PBYI $238,062,000.00
- Revenue This Year
- MCR N/A
- PBYI N/A
- Revenue Next Year
- MCR N/A
- PBYI N/A
- P/E Ratio
- MCR $16.61
- PBYI $5.33
- Revenue Growth
- MCR N/A
- PBYI 8.63
- 52 Week Low
- MCR $5.63
- PBYI $2.32
- 52 Week High
- MCR $6.70
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- MCR 50.40
- PBYI 65.12
- Support Level
- MCR $6.36
- PBYI $4.37
- Resistance Level
- MCR $6.50
- PBYI $4.79
- Average True Range (ATR)
- MCR 0.07
- PBYI 0.22
- MACD
- MCR -0.01
- PBYI 0.04
- Stochastic Oscillator
- MCR 40.11
- PBYI 97.89
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.